Sinobiopharma, Inc. (SNBP) Announces Second Quarter 2010 Financial Results Revenue Increases to Approximately $2.1 Million; Net Income Increases to Approximately $1.1 Million  
1/19/2010 9:38:30 AM

NANTONG CITY, China, Jan. 19 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. , a fully integrated and highly innovative biopharmaceutical company engaged in the research and development, manufacture and marketing of pharmaceutical products in China, today announced financial results for the second quarter ended November 30, 2009.

"We achieved excellent revenue and net income growth in the second quarter," said Dr. Lequn Huang, Sinobiopharma's Chairman and CEO stated. "The strong growth is largely due to our increased marketing efforts and strong demand for our main product KuTai (cisatracurium besylate). KuTai is replacing older-generation muscle relaxants since it is uniquely differentiated by both its performance profile and its convenience. KuTai is the only muscle relaxant that can be stored at room temperature. We feel confident that KuTai will continue to gain market share."

Business Outlook

Dr. Huang expects strong results to continue with the launch of Sinobiopharma's newest drug YiTai (perindopril), which has obtained all approvals for production. The Company believes that YiTai will be launched as a first-to-market drug and therefore will enjoy marketing exclusivity and a price premium. There has been strong demand for YiTai to date, and strong sales will help to diversify the revenue stream from Sinobiopharma's product portfolio.

About Sinobiopharma

Sinobiopharma Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.


This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward- looking statement, except as required under applicable law.

CONTACT: Sinobiopharma, Inc., Investor Relations, +1-203-987-5632